Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy
{{output}}
T-cells engineered to express CD19-specific chimeric antigen receptors (CD19 CAR-T cells) can achieve high response rates in patients with refractory/relapsed (R/R) CD19+ hematologic malignancies. Nonetheless, the efficacy of CD19-specific CAR-T cell therapy c... ...
